Palbociclib In Progressive Brain Metastases

Metastatic Malignant Neoplasm to Brain Clinical Trial

Official title: A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway

Status Recruiting

Clinical Trial Summary

This research study is studying palbociclib as a possible treatment for recurrent brain metastases.

• Pfizer, a pharmaceutical company, is supporting this research study by providing the study drug as well as funding for research activities

Clinical Trial Description

• This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

• This is a study designed to evaluate the efficacy and safety of palbociclib in recurrent brain metastases. Palbociclib is being studied for use in the treatment of a broad range of cancers. This type of drug inhibits cell growth in the cells called cyclin-dependent kinases which promote tumor cell proliferation.

• The FDA (the U.S. Food and Drug Administration) has not approved palbociclib for participants specific disease but it has been approved for other uses ;

Related Conditions & MeSH terms

• Brain Neoplasms
• Metastatic Malignant Neoplasm to Brain
• Neoplasm Metastasis
• Neoplasms

• NCT number: NCT02896335
• Study type: Interventional
• Source: Massachusetts General Hospital
• Contact: Priscilla Brastianos, MD
• Phone: 617-724-8770
• Email: PBRASTIANOS@mgh.harvard.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: February 14, 2017
• Completion date: September 2025